Skip to main content

Table 1 Patient characteristic (N = 77)

From: Effect of dose rate on pulmonary toxicity in patients with hematolymphoid malignancies undergoing total body irradiation

  Dose rate < 6 cGy/min (N = 23) Dose rate ≥ 6 cGy/min (N = 54) P-value
Age at TBI (year) 29.4 ± 18.6 (1.9–66.4) 15.9 ± 8.9 (1.8–41.7) 0.002b
Sex
 Male 14 (60.9%) 32 (59.9%) 0.895a
 Female 9 (39.1%) 22 (40.1%)  
Type of Cancer
 ALL 15 (65.2%) 32 (59.3%) 0.172a
 AML 2 (8.7%) 14 (25.9%)  
 Others 6 (26.1%) 8 (14.8%)  
Total dose (Gy) 11.7 ± 0.9 (9–12) 10.9 ± 1.1 (9–12) 0.004b
Daily dose (Gy) 3.0 ± 0.1 (2.5–3.0) 3.1 ± 0.2 (2.3–3.3) 0.001b
 Daily dose < 3 1 (4.3%) 2 (3.7%)  
 Daily dose ≥3 22 (95.7%) 52 (96.3%) 0.017a
Donor type
 Related 16 (69.6%) 22 (40.7%) 0.021a
 Unrelated 7 (30.4%) 32 (59.3%)  
Conditioning regimen
 Cyclophosphamide 4 (17.4%) 8 (14.8%) 0.271a
 Cyclophosphamide + otherc 14 (60.9%) 24 (44.4%)  
 Othersd 5 (21.7%) 22 (40.7%)  
Number of prior chemotherapy regimens
 1 3 (13.0%) 14 (25.9%) 0.193a
 2 8 (34.8%) 23 (42.6%)  
  ≥ 3 12 (52.2%) 17 (31.5%)  
  1. aP-value by chi-square test. bP-value by Mann-Whitney U test
  2. c Other: cytarabine, fludarabine, etoposide
  3. d Others: cytarabine/fludaraibine, busulfan/fludarabine/etoposide, melphalan, melphalan/fludarabine, thiotepa